Cozart DIP contract extended
Cozart, the medical diagnostics company, has had its contract with the Home Office to supply its Cozart RapiScan oral fluid drug testing system to the Drug Interventions Programme (DIP) extended until April 2007.
Cozart, the medical diagnostics company, has had its contract with the Home Office to supply its Cozart RapiScan oral fluid drug testing system to the Drug Interventions Programme (DIP) extended until April 2007.
The DIP programme identifies people charged with certain trigger offences who have taken the Class A drugs heroin, cocaine or crack cocaine. It then refers them for treatment in an attempt to break the link between Class A drug use and acquisitive crime.
The DIP programme uses the Cozart RapiScan oral fluid drug testing system to identify these users in 173 selected police custody sites across England and Wales.
Trigger offences currently include, inter alia, property crime, robbery and other specified Class A drug offences. Dr. Christopher Hand, Managing Director of Cozart, said; Cozart RapiScan has proved itself to be a highly effective diagnostic tool for the identification of class A drugs.
The expansion of the DIP has led to the device being used in 173 police custody sites. We believe that the market opportunity addressed by Cozart RapiScan is continuing to expand as the importance of on-site drug testing is increasingly recognised in society.
The company also announced the new role of Director of International Operations has gone to Paul Kennedy who has worked for Cozart since October 2004 on a consultancy basis.
He worked with Cozart on their recent acquisition of the Spanish medical diagnostics company, Spinreact SA and the acquisition of Medib Scandinavien in June 2005.